Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 17/20 | 0.59 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188422 | 0.94 | FGFR4 (0.66) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL27188430 | 0.94 | FGFR4 (0.66) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL30101139 | 0.86 | FGFR4 (0.76) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL27188387 | 0.86 | FGFR4 (0.76) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL27188670 | 0.83 | FGFR1 (0.53) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL27188671 | 0.83 | FGFR1 (0.53) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL22132921 | 0.82 | FGFR1 (0.63) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL22132910 | 0.82 | FGFR1 (0.63) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL22132909 | 0.82 | FGFR1 (0.63) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL22132789 | 0.81 | FGFR1 (0.64) | FGFR1FGFR4FGFR2FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-04-04 | — | — | US | claimed |
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR4 4/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.